ARTICLE | Clinical News
Compugen validates second B7/CD28 candidate
June 22, 2011 12:56 AM UTC
Compugen Ltd. (NASDAQ:CGEN) announced in vitro validation of CGEN-15021, its second candidate based on the B7/ CD28 co-stimulatory protein family with therapeutic potential in autoimmune diseases and...